Kendall Square

North River Leerink’s Successful 100 Chestnut Street Development Continues Somerville’s Growth as a Leading Life Science and Innovation Hub

Retrieved on: 
Thursday, February 29, 2024

At the heart of this transformation stands 100 Chestnut, a purpose-built 200,000 sq.

Key Points: 
  • At the heart of this transformation stands 100 Chestnut, a purpose-built 200,000 sq.
  • ft. Life Science building that is 90% leased, reflecting NRL's passion and focus on developing world-class buildings that enable innovation and support the creation of sustainable and vibrant communities.
  • Our goal is to contribute towards the development of a rich, vibrant and diverse district focused on fostering Art and enabling innovation in the Life Science/Biotech industry,” said Jeff Leerink, Managing Partner at NRL.
  • And most recently, ADA Forsyth, a leading institute dedicated to improving oral and overall health through innovative research and community outreach, has leased 76,000 sq.

LabCentral and Astellas Launch Inaugural $500,000 "Diamond Ticket" at LabCentral 238

Retrieved on: 
Tuesday, March 5, 2024

NORTHBROOK, Ill. and CAMBRIDGE, Mass., March 5, 2024 /PRNewswire/ -- LabCentral, the first-of-its-kind shared laboratory space designed as a launchpad for high-potential biotech startups, and Astellas Pharma US, Inc. (President: Mark Reisenauer, "Astellas") today announced the LabCentral 238 Diamond Ticket award. The Diamond Ticket is the largest lab space award of its kind in the industry and provides an innovative, growth-stage biotech company with a $500,000 credit for private lab space at LabCentral 238, one of the newest facilities in the LabCentral network in the heart of Kendall Square. Interested companies can review program details and apply online before the April 5, 2024 deadline.

Key Points: 
  • Astellas' support is a key part of its commitment to discovering and advancing innovative science.
  • "LabCentral 238 has expanded the options for growth-stage biotechs that need more space and specialized biomanufacturing equipment, enabling them to "grow" inside the LabCentral network of facilities and remain in Kendall Square," said Johannes Fruehauf, co-founder and president of LabCentral.
  • "From the beginning, Astellas has been much more than a founding sponsor; they have been a true partner.
  • A select number of entrepreneurs will be invited to present virtually to a joint selection committee made up of representatives from LabCentral and Astellas in April 2024.

Meliora Therapeutics Establishes Leadership Team with Key Promotion and New Addition

Retrieved on: 
Monday, February 12, 2024

“These leadership updates mark the beginning of a new phase for Meliora.

Key Points: 
  • “These leadership updates mark the beginning of a new phase for Meliora.
  • We are also excited to welcome Anand, whose experience in cancer biology will be critical in advancing the company’s mission,” said David Li, co-founder and CEO of Meliora Therapeutics.
  • Dr. Claudio Chuaqui’s promotion to CSO comes as Meliora rapidly progresses multiple projects in its internal pipeline under his leadership and expertise.
  • Meliora Therapeutics is discovering and developing small molecule oncology therapies for high value cancer targets with its proprietary machine learning powered platform, AnchorOmics.

KBRA Assigns Preliminary Ratings to BX 2024-BIO

Retrieved on: 
Monday, January 22, 2024

KBRA announces the assignment of preliminary ratings to four classes of BX 2024-BIO, a CMBS single-borrower securitization.

Key Points: 
  • KBRA announces the assignment of preliminary ratings to four classes of BX 2024-BIO, a CMBS single-borrower securitization.
  • The collateral for the transaction is a $1.2 billion floating rate, interest-only mortgage loan.
  • The loan has an initial two-year term with three, one-year extension options and requires monthly interest-only payments based on a SOFR cap of 4.00%.
  • The loan is secured by the borrower’s fee simple interest in the Kendall Square Portfolio (“Kendall Square”) and Gateway of Pacific Phase I (“GoP Phase I”) property.

Arena BioWorks Launches as a Privately Funded, Fully Independent Biomedical Institute to Shorten the Path from Insight to Therapeutics

Retrieved on: 
Friday, January 12, 2024

By relying solely on private funding, Arena will be able to quickly translate insight into discovery, distinguishing it from traditional models.

Key Points: 
  • By relying solely on private funding, Arena will be able to quickly translate insight into discovery, distinguishing it from traditional models.
  • Arena will support development efforts with its drug discovery platforms through preclinical studies and beyond, when appropriate.
  • When Arena's human biology approach elucidates a disease mechanism, Arena will form a company to translate that insight to the clinic.
  • These emerging companies, which might recruit external scientists and leaders, will all be developed within the resource-rich ecosystem of Arena.

Introducing Portal Biotechnologies

Retrieved on: 
Tuesday, December 12, 2023

Portal Biotechnologies, Inc., a cell engineering platform company, announced its emergence from stealth today.

Key Points: 
  • Portal Biotechnologies, Inc., a cell engineering platform company, announced its emergence from stealth today.
  • Established in 2023, Portal is implementing a simplified approach to intracellular delivery, focused on accelerating advances in RNA, gene editing, and AI-driven discovery technologies.
  • Portal was founded by Armon Sharei, PhD., founder and former CEO of SQZ Biotechnologies.
  • Under the ‘Powered by Portal’ model, the company is integrating its single-use cartridges with existing high throughput robots and clinical manufacturing equipment.

Vicinity Energy Steams Ahead to Sustainable Future with Arrival of 42MW Electric Boiler in Cambridge, Mass.

Retrieved on: 
Tuesday, November 28, 2023

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20231128438047/en/
    Vicinity's 42MW electric boiler arrived at Vicinity's Kendall facility in Cambridge, MA.
  • (Photo: Business Wire)
    Installing the electric boiler marks a significant stride in Vicinity's commitment to sustainable practices and reducing carbon emissions.
  • The newly acquired 42MW electric boiler will play a pivotal role in Vicinity Energy's mission to provide sustainable solutions to its customers.
  • "This 42MW electric boiler represents a significant leap forward in our decarbonization efforts for Boston, Cambridge and the Commonwealth.

BXP Agrees to Sell a 45% Interest in Kendall Square Life Sciences Properties

Retrieved on: 
Tuesday, November 14, 2023

BXP (NYSE: BXP), the largest publicly traded developer, owner, and manager of premier workplaces in the United States, today announced that it has entered into agreements to sell a 45% interest in two life sciences development properties located in Kendall Square in Cambridge, Massachusetts, to Norges Bank Investment Management at a gross valuation of approximately $1.66 billion or $2,050 per square foot.

Key Points: 
  • BXP (NYSE: BXP), the largest publicly traded developer, owner, and manager of premier workplaces in the United States, today announced that it has entered into agreements to sell a 45% interest in two life sciences development properties located in Kendall Square in Cambridge, Massachusetts, to Norges Bank Investment Management at a gross valuation of approximately $1.66 billion or $2,050 per square foot.
  • The properties – 290 Binney Street and 300 Binney Street – total 810,000 square feet and are each 100% pre-leased.
  • BXP will retain a 55% interest in the joint ventures and will provide development, property management, and leasing services for the ventures.
  • “We are delighted to deepen our longstanding partnership with Norges Bank Investment Management,” said Owen Thomas, Chairman & CEO, BXP.

Bayer and Broad Institute of MIT and Harvard Extend Research Collaboration to Develop New Cancer Therapies

Retrieved on: 
Thursday, November 2, 2023

Bayer and the Broad Institute of MIT and Harvard today announced that they have extended their research collaboration of 10 years by an additional five years, to develop and advance innovative cancer treatments.

Key Points: 
  • Bayer and the Broad Institute of MIT and Harvard today announced that they have extended their research collaboration of 10 years by an additional five years, to develop and advance innovative cancer treatments.
  • “Bayer’s established collaboration with the Broad Institute has already resulted in three clinical oncology candidates.
  • Bayer with its Bayer Research & Innovation Center (BRIC) is closely located to the Broad Institute in Kendall Square, Cambridge, MA.
  • BRIC houses a center of precision oncology research equipped with state-of-the-art laboratories for the development of targeted next-generation cancer therapies for patients.

Dr. Benjamin Wolozin to Present "Development of Orally Available, Brain Penetrant Compound Reducing Tau Pathology" at CTAD 2023

Retrieved on: 
Tuesday, October 24, 2023

CAMBRIDGE, Mass., Oct. 24, 2023 /PRNewswire/ -- Aquinnah Pharmaceuticals, leaders in stress granule biology that afflict a wide range of neurodegenerative disorders, today announced that the company's Co-Founder and Chief Scientific Officer, Dr. Benjamin Wolozin MD, Ph.D., will be presenting new preclinical research at the 2023 Clinical Trials on Alzheimer's Disease (CTAD) conference. CTAD is the premier industry event highlighting new research and breakthroughs in the areas of disease-modifying agents, gene therapy, vaccines and multimodal interventions.

Key Points: 
  • CTAD is the premier industry event highlighting new research and breakthroughs in the areas of disease-modifying agents, gene therapy, vaccines and multimodal interventions.
  • CTAD 23 is sold out, but attendees can still register for virtual attendance.
  • Our therapeutic removes abnormal tau protein, which is the key protein contributing to loss of memory and cognition in Alzheimer's disease.
  • If successful in clinical trials, Aquinnah's treatment offers the hope of reducing the brain damage and correspondingly restoring brain function for patients suffering from Alzheimer's disease."